DKA Treatment Algorithm
For moderate-to-severe DKA, initiate continuous intravenous insulin infusion at 0.1 units/kg/h with aggressive fluid resuscitation, potassium replacement, and close monitoring; mild-to-moderate DKA may be treated with frequent subcutaneous rapid-acting insulin in appropriate settings. 1, 2
Initial Assessment and Diagnosis
- Confirm DKA diagnosis with the triad: metabolic acidosis (pH <7.3, bicarbonate <18 mEq/L, anion gap >10 mEq/L), elevated ketones (serum preferred over urine), and typically hyperglycemia >250 mg/dL—though hyperglycemia has been de-emphasized due to increasing euglycemic DKA, particularly with SGLT2 inhibitor use 3, 4
- Obtain baseline labs: electrolytes, phosphate, BUN, creatinine, urinalysis, CBC with differential, A1C, and ECG 3
- Consider additional testing based on clinical presentation: amylase, lipase, hepatic transaminases, troponin, creatine kinase, blood/urine cultures, and chest X-ray 3
Fluid Resuscitation
- Begin aggressive fluid replacement immediately—this is critical for reversing metabolic derangements and correcting volume depletion 5, 6
- Administer isotonic saline initially for volume restoration 5
- Caution: Patients with heart failure, renal disease, or older age require tailored fluid strategies with careful monitoring to avoid volume overload 5
Insulin Therapy
Continuous IV Insulin (Preferred for Moderate-Severe DKA)
- Start continuous insulin infusion at 0.1 units/kg/h for moderate-to-severe DKA 1, 4
- Critical modification: When glucose drops below 14 mmol/L (252 mg/dL), consider de-escalating insulin infusion from 0.1 to 0.05 units/kg/h to reduce hypoglycemia risk 4
- Target glucose range: 100-180 mg/dL (5.6-10.0 mmol/L) during treatment 2
- Computer-guided algorithms (e.g., Glucommander) achieve faster DKA resolution (13.6 vs 17.3 hours) and lower hypoglycemia rates (12.9% vs 35%) compared to standard protocols, with optimal results using initial multiplier 0.01 and glucose target 120-180 mg/dL 7
Subcutaneous Insulin Alternative (Mild-Moderate DKA)
- Frequent subcutaneous rapid-acting insulin analogs combined with aggressive fluid management can be used for uncomplicated mild-to-moderate DKA in emergency departments or step-down units 1, 2
- This approach is safer and more cost-effective than IV insulin when adequate fluid replacement, frequent glucose monitoring, infection treatment, and appropriate follow-up are ensured 2
- During COVID-19, many centers successfully modified protocols to use subcutaneous insulin, substantially reducing point-of-care testing 1
Electrolyte Management
Potassium Replacement (Critical Priority)
- Hypokalaemia occurs in approximately 50% of DKA cases during treatment and severe hypokalaemia (<2.5 mEq/L) is associated with increased mortality 1
- Monitor potassium concentrations carefully and replace aggressively throughout treatment 1, 6
- Systematic assessment of potassium replacement protocols is warranted given the high complication rate 1
Dextrose Addition
- When glucose falls below 14 mmol/L (252 mg/dL), add dextrose-containing fluids (5% glucose-saline) while continuing insulin to suppress ketogenesis and prevent hypoglycemia 4, 8
Bicarbonate Therapy
- Bicarbonate use is generally NOT recommended—multiple studies show no difference in acidosis resolution or time to discharge, and it provides limited benefit even in severe acidosis 2, 8
Transition to Subcutaneous Insulin
- Transition when: stable glucose for 4-6 hours consecutively, normal anion gap, resolution of acidosis, hemodynamic stability (off vasopressors), and stable nutrition plan 1
- Critical timing: Administer basal insulin 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia and recurrent ketoacidosis 2
- Low-dose basal insulin analog added to IV insulin during transition may prevent rebound hyperglycemia without increasing hypoglycemia risk 2
Special Populations and Considerations
SGLT2 Inhibitor-Associated DKA
- SGLT2 inhibitors modestly increase DKA risk, particularly euglycemic DKA 3, 4
- Discontinue SGLT2 inhibitors 3-4 days before elective surgery to prevent perioperative euglycemic DKA 2, 8, 9
- Euglycemic DKA presents with normal or near-normal glucose but severe acidosis and ketonuria—maintain high clinical suspicion 4, 8
- Postoperative GI distension in SGLT2i users may signal impending euglycemic DKA 8
Patients with Renal Disease
- End-stage renal failure or dialysis patients require modified management approaches 4
- Adjust fluid and electrolyte replacement based on renal function 5
Pregnancy, Heart Failure, Acute Coronary Syndrome
- These comorbidities require tailored management strategies with careful fluid balance and monitoring 5
Monitoring During Treatment
- Check glucose every 2-4 hours minimum during treatment 2
- Monitor electrolytes, particularly potassium, frequently throughout treatment 1, 4
- Track anion gap and bicarbonate to assess acidosis resolution 2, 6
Prevention of Complications
- Hypoglycemia prevention: De-escalate insulin rate when glucose <14 mmol/L and add dextrose-containing fluids 4
- Hypokalaemia prevention: Aggressive monitoring and replacement throughout treatment 1
- Recurrent DKA prevention: Ensure adequate caloric intake, proper transition to subcutaneous insulin with 2-4 hour overlap, and patient education on recognition and management 2, 6